1. What Constitutes a Defect in Pharmaceutical and Medical Device Products?
A defect in pharmaceutical or medical device law typically falls into three categories, each with distinct legal implications for manufacturers. Manufacturing defects occur when the product deviates from its intended design due to production errors, contamination, or quality control failures. Design defects arise when the product conforms to the manufacturer's specifications, but the overall design creates an unreasonable risk of harm that could have been reduced by a safer alternative design. Warning defects occur when the manufacturer fails to disclose known risks or fails to provide adequate instructions for safe use.
Courts generally apply a risk-benefit analysis to design defect claims, weighing the severity of the potential harm against the burden of implementing a safer design. For pharmaceutical products, the concept of a defective design becomes more complex because medications inherently carry risks; the question is whether those risks were adequately disclosed and whether a safer formulation was feasible. Manufacturing defects typically carry the strongest liability exposure because they are objective departures from the intended product.
| Defect Type | Definition | Liability Standard |
| Manufacturing | Product deviates from intended design (contamination, error in production) | Strict liability; no need to prove negligence |
| Design | Product conforms to specifications but design creates unreasonable risk | Risk-benefit analysis; feasible alternative design required |
| Warning | Inadequate disclosure of known risks or failure to provide safe-use instructions | Failure to warn; duty to disclose known hazards |
The Role of Fda Approval and Regulatory Compliance
FDA approval of a drug or medical device does not provide immunity from products liability claims. Courts have consistently held that regulatory compliance is relevant but not dispositive; a product can meet FDA standards and still be found defective under state products liability law. Manufacturers must disclose to the FDA all known risks, adverse events, and post-market safety data. When a manufacturer withholds or misrepresents safety information to the FDA, or when post-market surveillance reveals risks not previously disclosed, the company faces significant liability exposure.
The FDA's approval process focuses on whether benefits outweigh known risks at the time of approval, not on whether a product is absolutely safe. This creates a gap: a product approved by the FDA may later be challenged as defectively designed or inadequately warned based on emerging evidence or a risk-benefit analysis that differs from the FDA's initial assessment. Corporations should treat regulatory approval as a baseline, not a shield.
2. How Do Courts Evaluate Pharmaceutical and Medical Device Defect Claims in Practice?
In practice, courts examine whether the manufacturer knew or should have known of the defect, whether adequate warnings were provided, and whether a feasible alternative design existed. For design defect claims, the plaintiff typically bears the burden of proving that a safer alternative design was both technologically and economically feasible. Expert testimony plays a central role; engineers, toxicologists, and medical professionals testify about the product's design, the nature of the defect, causation, and whether safer alternatives were available.
Pharmaceutical companies face heightened scrutiny when internal documents reveal that safety concerns were identified but not adequately communicated to consumers or healthcare providers. Discovery in products liability litigation often uncovers emails, research notes, and risk assessments that contradict public statements or marketing materials. Courts may view the failure to update warnings or the delay in reporting adverse events to the FDA as evidence of knowledge and deliberate disregard.
New York Courts and the Learned Intermediary Doctrine
In New York, courts apply the learned intermediary doctrine to prescription medications, which holds that a manufacturer's duty to warn is satisfied by providing adequate information to the prescribing physician, not directly to the patient. This doctrine significantly affects liability exposure for pharmaceutical companies because it limits direct warnings to end users. However, this protection is not absolute; if the manufacturer knows that the prescriber is unlikely to receive or understand the warning, or if the warning is inadequate even for a physician, the doctrine may not shield the manufacturer.
New York courts have also recognized exceptions when marketing directly to consumers creates a duty to warn the consumer, bypassing the learned intermediary. Corporations must carefully evaluate whether direct-to-consumer advertising, social media campaigns, or patient assistance programs create a duty to communicate risks directly to patients rather than relying solely on physician intermediation. The practical significance is that a company's marketing strategy can expand or contract its warning obligations under New York law.
3. What Are the Key Risk Areas for Manufacturers in Products Liability Claims?
The most significant risk exposure arises from the gap between what a manufacturer knows about a product's risks and what it communicates to regulators, healthcare providers, and consumers. Post-market surveillance data, adverse event reports, and internal safety assessments create a documentary record that plaintiffs' attorneys scrutinize for evidence of concealment or delay. Manufacturers who receive complaints about injuries or adverse events but fail to promptly investigate, report to the FDA, or update warnings face compounded liability.
A second critical risk area involves the adequacy of warnings themselves. Courts examine whether warnings are prominent, clearly state the nature and severity of the risk, and provide guidance on how to mitigate harm. Generic or buried warnings that fail to highlight serious risks may be found inadequate even if technically accurate. Corporations should document the rationale for warning language and ensure that updates to warnings reflect emerging safety data.
Documentation and Timing in Products Liability Exposure
From a practitioner's perspective, the timing and completeness of safety documentation directly affect litigation risk. When adverse events are reported to a company but not formally documented or investigated until months later, plaintiffs argue the delay reflects indifference to safety. In New York state courts, a common procedural hurdle arises when manufacturers have not preserved or organized post-market safety data in a way that demonstrates timely review and appropriate response; incomplete or delayed records can lead to adverse inferences at trial regarding what the company knew and when it knew it.
Corporations should establish protocols for receiving, investigating, and documenting adverse event reports. These protocols should include clear timelines for internal review, decision points for regulatory notification, and records showing the basis for any decision not to update warnings or recall the product. The absence of such documentation creates inference risk; courts may assume the company did not investigate or respond appropriately.
4. How Do Products Liability Claims Intersect with Consumer Products Law and Regulatory Obligations?
Products liability claims often overlap with broader consumer products law frameworks, which impose additional duties on manufacturers to ensure product safety and provide clear labeling. Under the Consumer Product Safety Commission Act and similar state statutes, manufacturers must report hazards, cooperate with recalls, and maintain records of safety testing and complaints. Failure to comply with these regulatory obligations can support a products liability claim and may trigger civil penalties or criminal exposure.
The intersection of products liability doctrine with regulatory compliance obligations means that a corporation's response to safety concerns must satisfy both tort law standards and administrative requirements. A product may be found defective under tort law even if the manufacturer complied with the FDA's current requirements, because tort law applies a different standard of reasonableness. Conversely, regulatory violations often serve as evidence of a defective product or inadequate warning.
Coordinating Internal Safety Protocols with Legal Obligations
Manufacturers should integrate their internal safety review processes with their legal obligations under products liability law and FDA regulations. This means establishing clear procedures for escalating safety concerns, documenting the basis for decisions, and ensuring that legal counsel is involved early when adverse events suggest a potential defect. The goal is to create a record demonstrating that safety was prioritized and that decisions were made on a reasoned basis, not that all adverse events were ignored or minimized.
Corporations should also consider whether their current warning language and product design reflect the current state of medical knowledge and available alternatives. Periodic review of warnings, particularly after new safety data emerges or competitive products introduce safer designs, reduces the risk that a court will find the company's warnings outdated or its design unreasonably dangerous relative to feasible alternatives.
Going forward, corporations should focus on three concrete steps: first, establish a formal adverse event tracking system that documents when complaints are received, how they are investigated, and what actions are taken; second, review existing warning language against current medical literature and competitor products to identify gaps; and third, ensure that decisions not to update warnings or initiate recalls are documented with the reasoning and evidence supporting that conclusion. These steps create a contemporaneous record that demonstrates reasoned judgment and can significantly reduce litigation exposure if claims later arise.
21 Apr, 2026
